Jazz Pharmaceuticals Reports Q3 2026 Results and Raises Full-Year Revenue Guidance

Executive Summary

On November 2, 2026, Jazz Pharmaceuticals plc furnished a Form 8-K under Item 2.02 disclosing financial results for the third quarter ended September 30, 2026. The company delivered record quarterly revenues of $1.24 billion (+10% YoY), driven by double-digit expansion in Xywav and strong oncology contributions, while raising full-year 2026 revenue guidance.

Key Financial Highlights

• Total Revenues: $1,243.0 million in 3Q26 compared to $1,126.1 million in 3Q25, representing 10% year-over-year growth.
• GAAP Net Loss: $(483.4) million ($(7.48) per share) in 3Q26 vs. GAAP net income of $251.4 million ($4.08 per share) in 3Q25.
• Non-GAAP Adjusted Net Loss: $(250.8) million ($(3.88) per share) vs. non-GAAP net income of $500.7 million ($8.13 per share) in 3Q25.
• IPR&D Impact: Both GAAP and non-GAAP results included $754 million in acquired in-process research and development (IPR&D) expense associated with the acquisition of Actio Biosciences, Inc., impacting GAAP and Non-GAAP EPS by $(11.32) and $(11.03), respectively.
• Operating Cash Flow: Generated $1.3 billion in cash from operations during the first nine months of 2026.
• 2026 Guidance Update: Raised full-year 2026 total revenue guidance to $4.775 billion – $4.850 billion.

Commercial & Pipeline Highlights

• Xywav: Net product sales grew 12% YoY to $482.8 million with ~425 net patient additions in 3Q26, reaching approximately 17,550 active patients.
• Epidiolex/Epidyolex: Net sales decreased 2% YoY to $295.4 million due to timing of gross-to-net deductions and wholesaler inventory patterns.
• Ziihera: Achieved net product sales of $20.6 million following FDA approval on August 25, 2026, for first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
• Zepzelca: Net sales increased 32% YoY to $104.4 million.
• Actio Acquisition: Closed in September 2026, adding ABS-1230 (JZP6979), a potential first-in-class precision medicine for KCNT1-related epilepsy.

Capital Allocation & Balance Sheet

• Issued $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032.
• Repurchased $225 million of ordinary shares in 3Q26, completing the July 2024 share repurchase authorization.
• Authorized a new $500 million share repurchase program with no expiration date in October 2026.
• Refinanced Term Loan B, reducing margin by 50 bps and extending maturity to May 2033.